Researchers analyzed 290 inpatients with recurrent C. diff infections at an academic medical center in a cohort study. Of the 109 patients treated with fecal transplant, 4.5 percent developed bloodstream infections, while 22 percent of the 181 patients receiving antibiotics developed bloodstream infections.
Patients receiving fecal transplants had a 23 percent lower bloodstream infection risk, along with 14 fewer days of hospitalization compared to the antibiotic group.
To view the full study, click here.
More articles on clinical leadership & infection control:
1st death from fecal transplant was at Massachusetts General Hospital
Serious deficiencies uncovered at MD Anderson Cancer Center, CMS report reveals
ACP updates colorectal cancer screening guidelines
